Compare SYF & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYF | VTRS |
|---|---|---|
| Founded | 1932 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5B | 21.0B |
| IPO Year | 2014 | 2019 |
| Metric | SYF | VTRS |
|---|---|---|
| Price | $71.80 | $21.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 12 |
| Target Price | ★ $87.00 | $21.00 |
| AVG Volume (30 Days) | 4.3M | ★ 8.6M |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | 1.90% | ★ 2.30% |
| EPS Growth | ★ 8.54 | N/A |
| EPS | ★ 7.52 | N/A |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $1.17 | $3.53 |
| Revenue Next Year | $5.11 | $3.69 |
| P/E Ratio | $9.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $63.08 | $10.15 |
| 52 Week High | $88.77 | $20.84 |
| Indicator | SYF | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 75.31 |
| Support Level | $69.23 | $16.02 |
| Resistance Level | $75.01 | N/A |
| Average True Range (ATR) | 2.28 | 0.57 |
| MACD | -0.37 | 0.21 |
| Stochastic Oscillator | 25.60 | 98.45 |
Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.